After Slow Start, Gates Foundation Ready To Boost Biotech Investment
This article was originally published in Start Up
Executive Summary
It’s been “a little shy” for a while, but the world’s richest charitable foundation has begun making equity investments in early-stage biotech companies that have promising technology for global health.
You may also be interested in...
Genocea Gets An Injection Of Capital As Early-Stage Studies Progress
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.